Trials / Completed
CompletedNCT04858568
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
PROSECO - A UK Multicentre Prospective Observational Study Evaluating COVID-19 Vaccine Immune Responses in Lymphoid Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 592 (actual)
- Sponsor
- University Hospital Southampton NHS Foundation Trust · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective observational study aims to evaluate the robustness and persistence of immune responses to vaccination, define factors associated with impaired immune responses and assess the incidence of COVID-19 infections in vaccinated individuals. To do this, we will collect peripheral blood from patients with lymphoid cancers before and after their COVID-19 vaccination. The blood will be explored in the laboratory for antibodies to SARS-CoV-2 and T-cell responses to the spike protein. Detailed clinical information will also be collated on about their cancer and treatment.
Conditions
- Classical Hodgkin Lymphoma
- Diffuse Large B Cell Lymphoma
- Primary Mediastinal B Cell Lymphoma
- High-grade B-cell Lymphoma
- Burkitt Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Marginal Zone Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Lymphoplasmacytic Lymphoma
- Nodular Lymphocyte Predominant Hodgkin Lymphoma
- Peripheral T-cell Lymphoma
Timeline
- Start date
- 2021-03-11
- Primary completion
- 2022-10-31
- Completion
- 2024-01-31
- First posted
- 2021-04-26
- Last updated
- 2024-02-06
Locations
9 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04858568. Inclusion in this directory is not an endorsement.